Global Generic Injectables Market Revenue To Record Robust Growth In Coming Years : FactMR

Global Generic Injectables: Market Segmentation

Fact.MR has studied the global generic injectables market with detailed segmentation on the basis of product type, container type, application and key regions.

Product Type

• Large Molecule Injectables:
• mAb
• Insulin
• Others
• Small Molecule Injectables

Container Type

• Vials
• Ampoules
• Premix
• Prefilled syringes
• Others

Application

• Oncology
• Infectious diseases
• Cardiology
• Diabetes
• Immunology
• Others

Key Regions

• North America
• Europe
• Asia Pacific
• Eastern Europe
• Latin America
• Middle East & Africa (MEA)

“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”

Global Generic Injectables Market- Scope Of The Report

The recent study by Fact.MR on global generic injectables market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that are currently determining the growth of generic injectables market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the manufacturing of generic injectables. The study also provides dynamics that are responsible for influencing the future status of the global generic injectables market over the forecast period.

A detailed assessment of the global generic injectables market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the global generic injectables market along with their product portfolio enhances the reliability of this comprehensive research study.

Global Generic Injectables Market: Report Summary

The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in global generic injectables market across the globe.

A comprehensive estimate of the global generic injectables market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the global generic injectables market during the forecast period. Price point comparison by region with global average price is also considered in the study.

Global Generic Injectables Market: Analysis on Market Size Evaluation

The global generic injectables market has been analyzed for each market segment, in terms of value (US$ Mn).

Market estimates at global and regional levels for generic injectables is available in terms of “US$ Mn” for value and thousand units for volume. A Y-o-Y growth contrast on prominent generic injectables market segments, along with market attractiveness evaluation has been incorporated in the report.

Global Generic Injectables Market: Inspected Assessment on Regional Segments

Key sections have been elaborated in the global generic injectables report, which have helped to deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the global generic injectables market during the forecast period.

Country-specific valuation on demand for generic injectables has been offered for each regional market, along with the market scope, estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

Global Generic Injectables Market: In-Depth Analysis on Competitive Landscape

The report sheds light on the leading manufacturers of global generic injectables along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of global generic injectables, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.

Key Takeaways of Global Generic Injectables Market Study:

• Large-molecule injectables are projected to capture an impressive market share, tantamount to 3/5th of the overall generic injectables market. Burgeoning research and development in biosimilar products and anticipated patent expiry of blockbuster molecules are projected to leverage market share.
• By container, the prefilled syringes segment shall witness rapid expansion, registering an impressive CAGR of 14.1% during the forecast period. Dose accuracy and ease of administration are key growth drivers of this segment.
• Oncology specialists are anticipated to find maximum applicability of generic injectables. Rising number of cancer patients has augmented the need to use generic formulae to develop affordable and quality drugs. The segment is projected to account for around 30% of the overall generic injectables market.
• Most of the generic drug administration is projected to take place via intravenous methods. Rapid and predictable delivery of drugs and avoidance of first-pass metabolism are key factors anticipated to leverage the intravenous administration segment.
• Asia-Pacific is set to emerge as the leader of the global generic injectables market. Accelerated demand for injectable antibiotics to treat diseases such as diarrhea, typhoid, malaria & cholera and increasing prevalence of cancers are set to uplift the region’s growth. A staggering CAGR of 16.1% is predicted for Asia-Pacific.
• North America is becoming increasingly lucrative, owing to a greater number of abbreviated new drug application (ANDA) approvals, rising demand for inexpensive biosimilar products and rising prevalence of lifestyle diseases. The region is anticipated to expand at a CAGR of 11.4% throughout the forecast period.
• Significant supply-chain disruptions may hinder growth prospects for the global generic injectables market during the forecast period. The COVID-19 outbreak has resulted in a nearly complete lockdown of the entire world, disrupting business transactions and transportation of essential commodities across the world. Limited transport facilities has generated a significant gap between the demand and supply of critical drugs.
• However, analysts project that the market shall soon experience an upsurge in pricing in the short-term. This is attributed to the fact that consumers will eventually be willing to pay a higher price for the drugs they consume as it is a necessity for them.

“The global generic injectables market shows massive growth potential in the future. Affordability of investment and comparatively lenient government regulations are propelling growth in the market. Companies are largely focused on developing new pipeline drugs to consolidate their market footprint,” concludes a Fact.MR analyst.

Developing Pipeline Drugs to Remain Forte of Market Players

The global generic injectables market include, but are not limited to, players such as  Pfizer, Inc., Novartis AG (Sandoz International GmbH), Baxter, Fresenius SE & Co., KGaA, Mylan N.V., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC., Lupin Ltd., Sanofi and Biocon.

Pfizer Inc., dominates the global generic injectables market, holding one-tenth of the total market share. Currently, the company is in the process of developing a formula titled PF-06881894, a biosimilar to Neulasta® for oncology practitioners. Likewise, it is also developing a biosimilar for Rheumatoid Arthritis titled PF-06410293. It has also developed Pfizerpen, a Penicillin G Potassium powder used as an antibiotic injection.

Sandoz Inc. is estimated to hold 1/20th of the global generic injectables market share. It also offers a strong biosimilar drugs pipeline. Its portfolio includes both blockbuster and niche products for all major therapeutic areas. Its generic drugs division includes Glatopa-based formulae such as Gilenya®, Afintor® and Glivec®. Sandoz operates globally through three franchises: retail generics, anti-infectives and biopharmaceuticals.